Scarica l'app Stockscreener
4.09
2.39%
-0.10
Dopo l'orario di chiusura:
4.14
0.05
+1.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PYXS Giù?
Forum
Previsione
Precedente Chiudi:
$4.19
Aprire:
$4.19
Volume 24 ore:
588.59K
Relative Volume:
1.12
Capitalizzazione di mercato:
$246.01M
Reddito:
-
Utile/perdita netta:
$-73.79M
Rapporto P/E:
-1.4401
EPS:
-2.84
Flusso di cassa netto:
$-77.44M
1 W Prestazione:
-13.71%
1M Prestazione:
+9.07%
6M Prestazione:
-1.45%
1 anno Prestazione:
+186.01%
Intervallo 1D:
$4.0464
$4.252
Intervallo di 1 settimana:
$4.0464
$4.87
Portata 52W:
$1.35
$6.85
Pyxis Oncology Inc Stock (PYXS) Company Profile
Nome
Pyxis Oncology Inc
Settore
Industria
Telefono
(617) 221-9059
Indirizzo
321 HARRISON AVENUE, BOSTON
Confronta PYXS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| PYXS | 4.09 | 246.01M | 0 | -73.79M | -77.44M | -2.84 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-11-02 | Iniziato | BofA Securities | Neutral |
| 2021-11-02 | Iniziato | Credit Suisse | Outperform |
| 2021-11-02 | Iniziato | Jefferies | Buy |
Pyxis Oncology Inc Borsa (PYXS) Ultime notizie
Brokerages Set Pyxis Oncology, Inc. (NASDAQ:PYXS) Price Target at $9.57 - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Up 19.3% in October - MarketBeat
Pyxis Oncology FY2024 EPS Forecast Lowered by HC Wainwright - MarketBeat
FY2024 EPS Estimates for Pyxis Oncology Reduced by Analyst - MarketBeat
Laurion Capital Management LP Adjusts Stake in Pyxis Oncology Inc - GuruFocus.com
Pyxis Oncology Inc (PYXS) Quarterly 10-Q Report - Quartzy
Pyxis Oncology to Host In-Person and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201 - Marketscreener.com
Pyxis Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pyxis Oncology reports Q3 EPS (35c), consensus (31c) - TipRanks
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024 - The Manila Times
Pyxis Oncology Reports Strong Cash Position, Clinical Progress in Q3 Update | PYXS Stock News - StockTitan
Pyxis Oncology to host investor event to present preliminary PYX-201 data - TipRanks
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor - GlobeNewswire
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201 - Marketscreener.com
Pyxis Oncology to Reveal Key Phase 1 Trial Data for Novel Cancer Drug PYX-201 | PYXS Stock News - StockTitan
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside - AOL
Pyxis Oncology (NASDAQ:PYXS) Now Covered by Analysts at Stephens - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Bought by abrdn plc - MarketBeat
Pyxis Oncology Inc (PYXS) Stock Price & Chart | Trade Now - Capital.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of “Buy” from Analysts - Defense World
Pyxis Oncology expands equity plan by 5.5 million shares - Investing.com India
Pyxis Oncology Q3 EPS Estimate Reduced by Leerink Partnrs - MarketBeat
Financial Metrics Exploration: Understanding Pyxis Oncology Inc (PYXS) Through Ratios - The Dwinnex
Examining Pyxis Oncology Inc (PYXS) stock is warranted - US Post News
Millennium Management LLC Buys 743,499 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - MarketBeat
Upward Trajectory: Pyxis Oncology Inc (PYXS) Posts a Slidee, Closing at 3.51 - The Dwinnex
Pyxis Oncology's SWOT analysis: ADC developer's stock faces pivotal readout - Investing.com
Rhumbline Advisers Takes Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Blue Owl Capital Holdings LP Purchases New Holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) - MarketBeat
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS) - PR Newswire
ShiftPixy stock plunges to 52-week low at $0.9 amid market challenges - Investing.com
Prepare Yourself for Liftoff: Pyxis Oncology Inc (PYXS) - SETE News
Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Bought by Bank of New York Mellon Corp - MarketBeat
ShiftPixy, Inc. Announces Reverse Stock Split Effective Date - Business Wire
Are Pyxis Oncology Inc’shares a good deal? - US Post News
Pyxis Oncology (NASDAQ:PYXS) Receives "Outperform" Rating from Royal Bank of Canada - MarketBeat
Market Insights: Pyxis Oncology Inc (PYXS)’s Notable Gain of 1.39, Closing at 3.66 - The Dwinnex
Earth Science Tech (OTCMKTS:ETST) vs. Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Comparison - Defense World
Moment Of Truth Approaches For Pyxis Oncology (NASDAQ:PYXS) - Seeking Alpha
Pyxis Oncology : Morgan Stanley 22nd Annual Global Healthcare Conference - Marketscreener.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Pyxis Oncology Inc (PYXS) looking to reclaim success with recent performance - SETE News
Have you been able to find a good deal on Pyxis Oncology Inc’s shares? - US Post News
Quarterly Snapshot: Quick and Current Ratios for Pyxis Oncology Inc (PYXS) - The Dwinnex
Pyxis Oncology to Participate in Two Upcoming Investor Conferences - GlobeNewswire
JAZZ: 3 Oncology Stocks With Major Upside - StockNews.com
PYXS Stock Earnings: Pyxis Oncology Misses EPS for Q2 2024 - MSN
Market Momentum Report: Pyxis Oncology Inc (PYXS)’s Positive Close at 3.62 - The Dwinnex
Q3 2024 EPS Estimates for Pyxis Oncology, Inc. Boosted by William Blair (NASDAQ:PYXS) - MarketBeat
Pyxis Oncology Inc Azioni (PYXS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):